

Information Request Email, July 24, 2014 - GARDASIL 9

RECORD OF EMAIL COMMUNICATION

Submission Type: BLA Submission ID: 125508/0 Office: OVRR

Product: Human Papillomavirus 9-valent Vaccine, Recombinant

Applicant: Merck Sharp & Dohme Corp.

Telecon Date/Time: 24-Jul-2014 11:54 AM

Initiated by FDA? Yes

Telephone Number: N/A (email)

Communication Categories: Advice and Information Request

Author: Laura Montague

Telecon Summary: IR #15 - LRP feedback and request that Merck submit updated LRP templates by 9-5-2014

FDA Participants: Laura Montague, Bharat Khurana

Non-FDA Participants: Alison Fisher

Trans-BLA Group: No

Related STNs: None

Related PMCs: None

Telecon Body:

From: Montague, Laura [mailto:Laura.Montague@fda.hhs.gov]

Sent: Thursday, July 24, 2014 11:54 AM

To: Fisher, Alison L

Cc: Khurana, Bharat

Subject: STN 125508/0; Information Request #15

Dear Alison,

Thank you for the responses to CBER's Information request #12, which were submitted in amendment 23 of STN 125508 on July 2, 2014. CBER has reviewed the amendment, and has the following comments regarding the lot release protocols for 125508:

Comments:

1. Merck agreed to add the STN (125126) next to the HPV bulks for Types 6, 11, 16 and 18.
2. On page 3, CBER had requested the last (b)(4) test date be included. CBER agrees with Merck's request that this additional --(b)(4)---- reporting information not be a requirement for batch release.
3. Merck agreed to change the reference to (b)(4).
4. Merck agreed to remove the test for -----(b)(4)-----.
5. On pages 4 and 5 CBER had requested positive control lot information be included in the template. Merck has requested to maintain the current formatting as provided in the draft lot release protocols. CBER agrees that Merck may maintain the current formatting without the addition of this information.

6. On page 6 CBER had requested the intercept value from the standard curve be included in the (b)(4) template. Merck has requested to maintain the current format. CBER agrees that the current format may be maintained.
7. On the (b)(4) draft lot release protocols, CBER had requested that Merck remove or change anything in the lot release protocol template that had been agreed to with CBER. Changes already agreed to were:
 - a. On page 3, testing the -----(b)(4)----- may be removed.
 - b. On page 6 of attachment 3, -----(b)(4)----- testing may be removed. Merck agreed to make these changes.
8. CBER agrees, as above in comment 2, that the template for sterility may be maintained as submitted.
9. CBER agrees that, for (b)(4) lot release protocols, the full (b)(4) template as submitted for the final container does not need to be used. The (b)(4) assay reporting format as described in the initially-proposed lot release protocols is sufficient and acceptable.
10. CBER agrees, as described above in comment 5, to allow Merck to maintain the template for the (b)(4) result table.
11. Merck agreed to remove the reference to electronic protocols from 125508 lot release protocol templates until Joe Quander has notified Merck that they may be sent electronically.
12. Merck agreed to add the specification to the templates once they have been agreed to with CBER.

Request and Advice:

(a) CBER requests that Merck submit updated lot release protocol templates for STN 125508 final container and bulks to the BLA once the agreed-upon corrections have been made. The templates should be submitted to the BLA by September 5, 2014.

(b) CBER's Sample Custodian will **not** receive lot release samples between Monday, August 1, 2014 and Friday, August 15, 2014. Samples sent after August 15, 2014 should use the new address for the White Oak Campus.

Thank you,

Laura

Laura Montague

Regulatory Project Manager

FDA/OMPT/CBER/OVRR

Division of Vaccines and Related Products Applications

WO71-3019

10903 New Hampshire Ave

Silver Spring, MD 20993-0002

phone: (301)796-2640

fax: (301)595-1244

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other

action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (One Merck Drive, Whitehouse Station, New Jersey, USA 08889), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.